个人简介
刘艳红，女，医学博士。研究方向为1）生物材料与CAR-T细胞疗法的交叉研究，通过开展mRNA核酸递送系统和可植入水凝胶材料在体内编辑免疫细胞，探索其治疗肝癌、胰腺癌的机制和药效。2）智能化细胞治疗的基础研究（CAR-T、CAR-NK、CAR-M细胞等）：设计智能化基因环路开关，编程免疫细胞，探究治疗实体瘤的药效和机制。目前以第一作者以Materials Today、Biomaterials等期刊发表多篇文章，参与国自然面上项目、省自然项目等。
研究方向
1）生物材料与CAR-T细胞疗法的交叉研究；2）智能化细胞治疗的基础研究
成果奖项：（近五年主要成果及奖励情况）
1）Co-delivery of Axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity[J].Journal of Nanobiotechnology, 2025, 23(1):194 (IF=12.6)
2）Biomimetic multifunctional nanodrugs enable regulating abnormal tumor metabolism and amplifying PDT-induced immunotherapy for synergistically enhanced tumor ablation[J]. Materials Today, 2023, 68:125-147. (IF=24.2)
3）Tumor microenvironment remodeling-based penetration strategies to amplify nanodrug accessibility to tumor parenchyma[J]. Advanced Drug Delivery Reviews, 2021, 172: 80-103.(IF=17.873)
4）Biomineralization-inspired dasatinib nanodrug with sequential infiltration for effective solid tumor treatment[J]. Biomaterials, 2021, 267: 120481.(IF=15.304)
